BR0109507A - Processo para preparação de forma i, cristalina, de carbegolina - Google Patents

Processo para preparação de forma i, cristalina, de carbegolina

Info

Publication number
BR0109507A
BR0109507A BR0109507-2A BR0109507A BR0109507A BR 0109507 A BR0109507 A BR 0109507A BR 0109507 A BR0109507 A BR 0109507A BR 0109507 A BR0109507 A BR 0109507A
Authority
BR
Brazil
Prior art keywords
cabergoline
crystalline form
carbegoline
preparation
crystalline
Prior art date
Application number
BR0109507-2A
Other languages
English (en)
Inventor
Attilio Tomasi
Stefania Magenes
Giuliano Rammella
Mario Ungari
Gianfranco Pallanza
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0109507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0109507A publication Critical patent/BR0109507A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE FORMA I, CRISTALINA, DE CABERGOLINA". Um processo para produzir forma cristalina I de cabergolina, cujo processo compreende cristalização da forma desejada de uma mistura de éter dietílico/tolueno compreendendo cabergolina bruto, seguido por recuperação e secagem dos cristais resultantes. Um solvato novo forma V de cabergolina, útil como intermediário, também é fornecido.
BR0109507-2A 2000-03-24 2001-03-19 Processo para preparação de forma i, cristalina, de carbegolina BR0109507A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (1)

Publication Number Publication Date
BR0109507A true BR0109507A (pt) 2002-12-10

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109507-2A BR0109507A (pt) 2000-03-24 2001-03-19 Processo para preparação de forma i, cristalina, de carbegolina

Country Status (31)

Country Link
US (2) US6727363B2 (pt)
EP (1) EP1272489B1 (pt)
JP (1) JP4184666B2 (pt)
KR (1) KR100827558B1 (pt)
CN (1) CN1188412C (pt)
AR (1) AR032449A1 (pt)
AT (1) ATE250601T1 (pt)
AU (2) AU780747B2 (pt)
BR (1) BR0109507A (pt)
CA (1) CA2402836A1 (pt)
CZ (1) CZ20023176A3 (pt)
DE (1) DE60100858T2 (pt)
DK (1) DK1272489T3 (pt)
EA (1) EA005928B1 (pt)
EE (1) EE05088B1 (pt)
ES (1) ES2208602T3 (pt)
GB (1) GB0007308D0 (pt)
HK (1) HK1052348B (pt)
HU (1) HUP0300591A3 (pt)
IL (2) IL150985A0 (pt)
MX (1) MXPA02009283A (pt)
MY (1) MY134189A (pt)
NO (1) NO20024321L (pt)
NZ (1) NZ521316A (pt)
PE (1) PE20011140A1 (pt)
PL (1) PL358253A1 (pt)
PT (1) PT1272489E (pt)
SI (1) SI1272489T1 (pt)
SK (1) SK13582002A3 (pt)
WO (1) WO2001070740A1 (pt)
ZA (1) ZA200206045B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
RS81804A (sr) * 2002-03-15 2006-10-27 Pharmacia Corporation Postupak za dobijanje kristalnog oblika kabergolina
PL372371A1 (en) * 2002-03-15 2005-07-25 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
AU2004238833A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
JPH08502759A (ja) 1993-08-18 1996-03-26 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
AU2081999A (en) 1998-01-13 1999-08-02 Astrazeneca Uk Limited Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity
CN1303286A (zh) 1998-03-27 2001-07-11 法玛西雅厄普约翰美国公司 卡麦角林在治疗多动腿综合征中的应用
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Also Published As

Publication number Publication date
EE05088B1 (et) 2008-10-15
US6727363B2 (en) 2004-04-27
KR100827558B1 (ko) 2008-05-07
DE60100858D1 (de) 2003-10-30
EE200200545A (et) 2004-04-15
CN1188412C (zh) 2005-02-09
DK1272489T3 (da) 2003-12-15
NO20024321D0 (no) 2002-09-10
AU6211001A (en) 2001-10-03
AU2005203071A1 (en) 2005-08-11
SI1272489T1 (en) 2004-02-29
CA2402836A1 (en) 2001-09-27
AR032449A1 (es) 2003-11-12
PE20011140A1 (es) 2001-11-01
EA005928B1 (ru) 2005-08-25
CZ20023176A3 (cs) 2003-02-12
AU2005203071B2 (en) 2007-10-18
JP4184666B2 (ja) 2008-11-19
HUP0300591A2 (hu) 2003-07-28
NZ521316A (en) 2004-05-28
US6953854B2 (en) 2005-10-11
MY134189A (en) 2007-11-30
SK13582002A3 (sk) 2003-04-01
CN1419554A (zh) 2003-05-21
NO20024321L (no) 2002-09-10
GB0007308D0 (en) 2000-05-17
EP1272489A1 (en) 2003-01-08
US20040092744A1 (en) 2004-05-13
AU780747B2 (en) 2005-04-14
PL358253A1 (en) 2004-08-09
US20030149067A1 (en) 2003-08-07
JP2003528100A (ja) 2003-09-24
EP1272489B1 (en) 2003-09-24
HK1052348B (zh) 2005-09-16
PT1272489E (pt) 2004-02-27
IL150985A0 (en) 2003-02-12
MXPA02009283A (es) 2003-03-12
HUP0300591A3 (en) 2009-01-28
KR20020081587A (ko) 2002-10-28
EA200201016A1 (ru) 2003-02-27
IL150985A (en) 2007-03-08
ES2208602T3 (es) 2004-06-16
WO2001070740A1 (en) 2001-09-27
DE60100858T2 (de) 2004-07-29
HK1052348A1 (en) 2003-09-11
ZA200206045B (en) 2003-07-29
ATE250601T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
SE0103046L (sv) Kristallin bas av citalopram
BR9712073A (pt) Processo para produção de compostos de ecteinascidina
CR6368A (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
NO20052912D0 (no) Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
BR9714510A (pt) Processo e preparo de esteróides de 9,11-époxi e intermediários úteis dos mesmos
MY134189A (en) Process for preparing crystalline form i of cabergoline
BR0202518A (pt) Método para produção de uma composição, composição, e, método para aderir um material a um substrato
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
BR0301667A (pt) Processo para a preparação de polìmeros em emulsão com pureza elevada
UA72895C2 (uk) Нова кристалічна модифікація n торасеміду
CO5261596A1 (es) Derivados de cromano como compuestos estrogenicos, y su uso en la fabricacion de medicamentos para tratamientos relaionados con los receptores de estrogenos
AR037005A1 (es) Derivados de acidos dimetilfenilaceticos, derivados de piperidina, y proceso para la produccion de derivados de piperidina.
ID26346A (id) PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT
AR027559A1 (es) Metodo para la preparacion de citalopram
CO4700300A1 (es) Procedimiento para preparar olanzapina
SI1049686T1 (sl) Intermediati in postopki, uporabni pri semisintezi paklitaksela in analogov
EA200201236A1 (ru) Новый полиморф v торасемида
MXPA04008935A (es) Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
EA200201003A1 (ru) Аморфная модификация торасемида
ES2061871T3 (es) Un procedimiento para la preparacion de una antraciclinona 4-sustituida.
AR015924A1 (es) Procedimiento para la preparacion de derivados aminicos de alquiloxi-furanona,compuestos procedentes de este procedimiento, utilizacion de estos compuestosy compuestos intermediarios
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
BR9910603A (pt) Método aprimorado paraa preparar derivados de norbenzomorfano valiosos farmaceuticamente

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.